---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-23-000062"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:14:39.648509+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lisata Q3 net loss $5.3M; ASCEND ~95% enrolled, BOLSTER first patients treated

## Summary
- Net loss of $5.3M in Q3 2023 (vs $37.4M prior year which included $30.4M merger costs); cash $54.4M.
- ASCEND study (~95% enrollment) received positive interim futility analysis; topline data from Cohort A expected as early as Q4 2024.
- First patients treated in BOLSTER basket trial for head and neck and cholangiocarcinoma cohorts.
- Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and pancreatic cancer (EU).
- Cash runway into early 2026; expected to fund all ongoing trials through data.

## SEC filing metadata
- accession: 0000320017-23-000062
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001723000062/0000320017-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001723000062/clbs-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-23-000062
- JSON: https://secwatch.observer/filing/0000320017-23-000062.json
- Plain text: https://secwatch.observer/filing/0000320017-23-000062.txt

## Key facts
- Earnings Releases
  LISATA THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001723000062/0000320017-23-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.